CClinicalTrials.gg
CompletedNCT00357435Updated Dec 12, 2019

Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases

An observational study in Corneal Dystrophies, Hereditary and Corneal Disease, sponsored by National Eye Institute (NEI). Completed at 6 sites in 3 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2019-12-12.

Sponsored by National Eye Institute (NEI) · Observational

Study type
Observational
Enrollment
86
Ages
4 Years and older
Sex
All
01

Study summary

This study will explore the clinical and hereditary (genetic) features of corneal dystrophy and other inherited corneal disease. Corneal dystrophy is clouding of the cornea - the transparent part of the eye covering the iris and pupil that passes light to the back of the eye. When the cornea becomes cloudy, interfering with the passage of light, vision may be impaired or lost. Corneal problems may occur with vision problems alone, or with other problems, such as changes in facial appearance or bone or joint problems. A better understanding of these genetic conditions may help in the development of better diagnostic tests and methods of disease management.

Patients with corneal dystrophies and related corneal disease and their family members may be eligible for this study. Participants will be drawn from patients enrolled in other studies of corneal dystrophy at the NEI and collaborating clinics.

Participants will undergo the following tests and procedures:

  • Medical and surgical history
  • Verification of diagnosis
  • Construction of a family tree regarding familial vision problems
  • Complete eye examination, including dilation of the pupils and photography of the cornea, tests of color vision, field of vision, and the ability to see in the dark, and photographs of the eye.
  • Blood sample collection to identify the genes responsible for corneal disease and ascertain how they cause disease.
Read the detailed description

Objective: This project, Clinical and Molecular Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases will study the inheritance of corneal dystrophy and other inherited corneal diseases, both Mendelian and complex in order to identify the genes that, when mutated, cause corneal disease and the pathophysiology through which they act.

Study Population: Families of many nationalities and ethnic backgrounds. We will study a maximum or 2,000 patients and family members.

Design: The study consists of ascertaining individuals, and especially families with multiple individuals, affected by corneal dystrophy and other inherited corneal diseases. These patients and their families will undergo detailed ophthalmological examinations to characterize their corneal disease and determine their affectation status. A blood sample will be collected from each individual for isolation of DNA and in some individuals for lymphoblastoid transformation to establish a renewable source of DNA. Linkage analysis, physical mapping, and mutational screening will be carried out to identify the specific the gene and the mutations in it that are associated with corneal disease in this family. If necessary, the gene product will be characterized biochemically. All associate investigators will carry out patient ascertainment, diagnosis, and sample referral, and in some cases molecular genetic analyses. The study will enroll subjects at NEI and collaborating institutions.

Outcome Measures: Linkage will be determined using the lod score method and mutations in specific genes will be assessed using a combination of residue conservation, blosum score, and molecular modeling. Biochemical, metabolic, and physiological effects will be individualized to the specific assay.

02

Conditions studied

  • Corneal Dystrophies, Hereditary
  • Corneal Disease

Keywords

  • Cornea
  • Genetics
  • Dystrophy
  • Gene
  • Mapping
  • Molecular
  • Bietti
  • Fleck
  • Positional Cloning
  • Linkage
03

In context

Corneal Dystrophies, Hereditary

58 studies on the registry are indexed under Corneal Dystrophies, Hereditary; 11 are open to participants now.

This study's enrollment of 86 is below the median of 213 across 20 observational studies indexed under Corneal Dystrophies, Hereditary.

Browse Corneal Dystrophies, Hereditary studies →

Lead sponsor

National Eye Institute (NEI) is the lead sponsor of 266 studies on the registry; 17 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 8 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Subjects with the following will be recruited:

  1. Individuals or family members of individuals with corneal dystrophies and related corneal diseases.
  2. Adults must be capable of providing their own consent.
  3. All subjects must be able to cooperate with study examination and phlebotomy.
  4. Older than 4 years of age.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Diseases, infections, or trauma that mimic corneal diseases.
  2. Children requiring sedation for study procedures.
05

Study design

Enrollment
86 participants (actual)
06

Study locations

6 sites
  • Jules Stein Eye Institute, UCLA
    Los Angeles, California, United States
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
  • Cleveland Clinic
    Cleveland, Ohio, United States
  • University of Texas, Houston
    Houston, Texas 77030, United States
  • Zhongshan Opthalmic Center
    Guangzhou, China
  • Seconda Universita degli
    Naples, Italy
07

References and documents

Publications

  • Klintworth GK, Sommer JR, Obrian G, Han L, Ahmed MN, Qumsiyeh MB, Lin PY, Basti S, Reddy MK, Kanai A, Hotta Y, Sugar J, Kumaramanickavel G, Munier F, Schorderet DF, El Matri L, Iwata F, Kaiser-Kupfer M, Nagata M, Nakayasu K, Hejtmancik JF, Teng CT. Familial subepithelial corneal amyloidosis (gelatinous drop-like corneal dystrophy): exclusion of linkage to lactoferrin gene. Mol Vis. 1998 Dec 31;4:31. PubMed 9873069 ↗
  • Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Chader GJ. Identification, isolation, and characterization of a 32-kDa fatty acid-binding protein missing from lymphocytes in humans with Bietti crystalline dystrophy (BCD). Mol Genet Metab. 1998 Oct;65(2):143-54. doi: 10.1006/mgme.1998.2723. PubMed 9787106 ↗
  • Jiao X, Munier FL, Iwata F, Hayakawa M, Kanai A, Lee J, Schorderet DF, Chen MS, Kaiser-Kupfer M, Hejtmancik JF. Genetic linkage of Bietti crystallin corneoretinal dystrophy to chromosome 4q35. Am J Hum Genet. 2000 Nov;67(5):1309-13. doi: 10.1016/S0002-9297(07)62960-7. Epub 2000 Sep 21. PubMed 11001583 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00357435
Lead sponsor
National Eye Institute (NEI)
Responsible party
Sponsor
First posted
Jul 27, 2006
Start date
Oct 6, 2003
Completion
Jul 21, 2016
Last update
Dec 12, 2019

Study contacts

James F Hejtmancik, M.D.
principal investigator · National Eye Institute (NEI)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion